Capecitabine Patent Expiration

Capecitabine is Used for treating tumors. It was first introduced by Cheplapharm Arzneimittel Gmbh in its drug Xeloda on Apr 30, 1998. 15 different companies have introduced drugs containing Capecitabine.


Capecitabine Patents

Given below is the list of patents protecting Capecitabine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xeloda US5472949

(Pediatric)

N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same Jun 14, 2014

(Expired)

Cheplapharm
Xeloda US5472949 N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same Dec 14, 2013

(Expired)

Cheplapharm



Capecitabine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Capecitabine Generic API Manufacturers

Several generic applications have been filed for Capecitabine. The first generic version for Capecitabine was by Teva Pharmaceuticals Usa Inc and was approved on Sep 16, 2013. And the latest generic version is by Hetero Labs Ltd Unit V and was approved on Mar 5, 2024.

Given below is the list of companies who have filed for Capecitabine generic, along with the locations of their manufacturing plants worldwide.